ClinicalTrials.gg
TerminatedNCT03402737Updated Feb 18, 2021

SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N

An interventional study of Stereotactic body radiotherapy in Head and Neck Neoplasm, sponsored by University Hospital, Ghent. Terminated at 3 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Treatment

Why this study was terminated
Poor recrual.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2017, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Head and Neck Neoplasms by University Hospital, Ghent — 1 open to participants now, 1 under way, none of them phase 3. Head and Neck Neoplasms · University Hospital, Ghent.

Enrollment
9th of 10
6 · median 18
Started
2017
the only one that year
No phase
5 of 11
1 open now
Registered
7th of 11
by date

Among the 11 studies in Head and Neck Neoplasms by University Hospital, Ghent, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2017, is one of 5 with no phase, and was the 7th registered.

Head and Neck Neoplasms

2,716 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

1 of the 11 studies in Head and Neck Neoplasms by University Hospital, Ghent is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 455 Head and Neck Neoplasms studies recruiting now, 347 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Head and Neck Neoplasms by University Hospital, Ghent, or all of them as a file.
02

Study summary

To derive the maximum tolerated dose of hypofractionated stereotactic body radiotherapy (SBRT) using dose painting by numbers with immunomodulating systemic therapy in patients that are reirradiated for recurrent squamous cell carcinoma of the head and neck.

Read the detailed description

The standard treatment in inoperable locally or regionally recurrent head and neck cancer has long been palliative systemic therapy using the so-called EXTREME-scheme: a combination of cisplatin, 5-fluorouracil and cetuximab. This therapy remains without realistic chances of cure. More recently, immunotherapy using nivolumab has demonstrated to result in long-term disease control of 1-2 year in cisplatin-refractory recurrent or metastatic head and neck cancer, however only in a small portion of patients (13%).

Fractionated high-dose local or regional re-irradiation is mostly given in a 6-7 weeks scheme. Using stereotactic body radiotherapy (SBRT), high radiotherapy doses can be given in a short time span. Severe late adverse events have been reported using SBRT but seem less frequent than in patients re-treated with conventional schedules. A possible solution to be able to administer higher doses is combining SBRT with dose painting, thus giving these high doses on small subvolumes only.

Addition of concomitant therapy to reirradiation may further improve outcomes due to radiosensitization and direct cytotoxicity. Therefore the investigator aims to combine high doses with concomitant therapy in the proposed study.

The immunomodulatory effect caused by radiation has been demonstrated both in animal models and clinical trials and leads to an enhanced local control as well as to eradication of distant metastasis. This so-called abscopal effect is reached through a systemic immune response evoked by the release of damage-associated molecular patterns (DAMPs) by the dying tumor-cells, also called immunogenic cell death (ICD).

The investigator hypothesizes that an abscopal effect could be present for patients presenting locoregional recurrent disease with asymptomatic distant metastases, thereby offering at least symptom control at the primary site while palliative systemic treatment could be postponed.

The proposed protocol focuses on patients with bad prognosis, as determined by a short timespan between primary therapy and recurrence (defined as 6-24 months after the end of the primary radiotherapy). It would bring the practical advantage of only 2-3 patient visits for the radiotherapy instead of ± 30-35 visits over 6-7 weeks. This shorter treatment schedule is expected to result in a direct gain in quality-of-life due to locoregional symptom control. It can also be expected that rescue systemic therapy will be postponed to a later stage of disease development, thereby prolonging overall survival.

The combination with systemic agents that are involved in immunogenic cell death bear the potential to result in a higher number of patients with longer periods of disease control and survival. The current standard of care, i.e. the combined systemic treatment with cisplatin - 5-fluorouracil - cetuximab, or nivolumab in case of former cisplatin use, can be used as a rescue regimen in case of therapy failure. In that sense, better overall survival from time of diagnosis of the index locoregional recurrent disease is expected.

03

Conditions studied

  • Head and Neck Neoplasm

Keywords

  • Stereotactic body radiotherapy
  • Immunomodulating systemic therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx or cancer of unknown primary (CUP) in the neck in previously irradiated tissue, with former irradiation with curative intent.
  • Patients with non-symptomatic distant and local, regional or combined locoregional recurrence can be included.
  • In case of non-metastatic disease, the recurrence must be primarily unresectable recurrence and/or patients refused surgery.
  • Time interval 6-24 months after the end of the initial radio(chemo)therapy for primary head and neck cancer.
  • Decision of the Head and Neck Tumor Boards at the recruiting centre to offer salvage radio(chemo)therapy, palliative chemotherapy or antibody treatment with nivolumab for cisplatin- locoregional recurrent head and neck squamous cell carcinoma.
  • performance status ≥ 70.
  • Age ≥ 18 years old.
  • obtained, signed and dated before specific protocol procedures.

Exclusion criteria

Exclusion Criteria:

  • Previous radiotherapy was for cT1-2 cN0 M0 glottic cancer.
  • Grade ≥ 4 late toxicity after the initial radio(chemo)therapy.
  • Brachytherapy as treatment for second primary / recurrence.
  • Previous (combination with) immunotherapy for the primary or the recurrent squamous cell carcinoma.
  • Impossibility of oral intake of cyclophosphamide.
  • For patients receiving cyclophosphamide: necessary intake during therapy of allopurinol, amiodarone, digoxin, hydrochlorothiazide, indomethacin, phenobarbital, phenytoin, warfarin. clopidogrel, ticlopidine, carbamazepine, efavirenz, rifampicin, ritonavir
  • High risk for arterial blow-out: 1 of following criteria is sufficient to exclude patients:

    1. soft tissue necrosis
    2. skin invasion of the recurrent cancer
    3. circumferential involvement of > 180° of a carotid artery
  • Symptomatic distant .
  • Other uncontrolled second primary tumors.
  • Pregnant or lactating women.
  • Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
  • Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Stereotactic body radiotherapy + IM

    Single arm phase I trial with 3 Stereotactic Body Radiation Therapy dose-escalation arms.

    Radiation: Stereotactic body radiotherapy

Interventions

  • RadiationStereotactic body radiotherapy

    The range of dose-painting will be escalated in following levels: * 2x 6-8Gy (day 1-4) * 3x 6-8Gy (day 1-4-7) * 3x 6-10Gy (day 1-4-7) * 3x 6-12Gy (day 1-4-7) Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks. Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide.

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. maximum tolerated dose

    maximum tolerated dose of hypofractionated stereotactic body radiotherapy (SBRT) using dose painting by numbers with immunomodulating systemic therapy in patients that are reirradiated for recurrent squamous cell carcinoma of the head and neck

    Time frame: 3 months after radiotherapy

Secondary outcomes

  1. symptom palliation - pain

    reduction in pain

    Time frame: through study completion, an average of 12 months

  2. symptom palliation - dysphagia

    reduction in grade of dysphagia

    Time frame: through study completion, an average of 12 months

  3. local control

    Assessment of: 1. diameter of target lesion of SBRT (and, if present, non-target lesions) in mm 2. tumor response according to recist criteria

    Time frame: 3 months after SBRT and thereafter through study completion, an average of 12 months

  4. Overall survival

    To estimate overall survival

    Time frame: through study completion, an average of 12 months

  5. Progression free survival

    To estimate progression-free survival

    Time frame: through study completion, an average of 12 months

  6. grade ≥ 3 toxicity-free survival

    To estimate grade ≥ 3 toxicity-free survival (anemia, febrile neutropenia, fatigue, dysphagia, oral mucositis, laryngeal mucositis, pharyngeal mucositis, pharyngeal hemorrhage, pharyngeal necrosis, pharyngeal stenosis, pharyngolaryngeal pain, dry mouth)

    Time frame: through study completion, an average of 12 months

  7. QOL - general

    To assess quality-of-life: EORTC QLQ

    Time frame: before therapy, week 3, week 6, week 10, week 14

  8. QOL - H&N specific

    To assess quality-of-life: H\&N35

    Time frame: before therapy, week 3, week 6, week 10, week 14

  9. topographic distribution of recurrence

    To assess the topographic distribution of recurrence (inside/outside FDG-avid GTV)

    Time frame: through study completion, an average of 12 months

  10. time to further treatment

    To assess time to further treatment

    Time frame: through study completion, an average of 12 months

  11. immune response

    To assess the immune response

    Time frame: using serum taken before treatment and at each fraction of SBRT, at weeks 6-14

07

Study locations

3 sites
  • Radiotherapy department, University Hospital Ghent
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven
    Leuven, Belgium
  • CHU Namur
    Namur, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Dec 2020, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Jan 18, 2018
StartActual
Jul 31, 2017
Primary completionActual
Dec 3, 2020
CompletionActual
Dec 3, 2020
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03402737
Responsible party
Radiotherapie (Principal Investigator, University Hospital, Ghent) — Principal investigator
First posted
Jan 18, 2018
Start date
Jul 31, 2017
Primary completion
Dec 3, 2020
Completion
Dec 3, 2020
Last update
Feb 18, 2021

Study contacts

Fréderic Duprez, MD, PhD
principal investigator · Gent University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion